Naturally repairing or reversing damage caused by degenerative disease

Frequency is pioneering a new class of small-molecule therapeutics to selectively activate progenitor cells already present within the body to create healthy functional tissues and organs.

Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Sensorineural hearing loss (FX-322)
Phase 2

Next anticipated milestones

  • Initiate Phase 2a trial 4Q19
  • Report top-line data 2H20

Commercial rights

US: Frequency Therapeutics
Ex-US: Astellas Pharma, Inc.

Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Multiple Sclerosis
Discovery

Next anticipated milestones

  • IND submission 2H21

Expanded Access Policy

Learn about our expanded access policy.

Our Program for Sensorineural Hearing Loss

Advancing FX-322 into a Phase 2a clinical study for the most common form of hearing loss

Learn More

Our Program for Multiple Sclerosis

Discovery science focused on activating progenitor cells in the central nervous system to repair myelin

Learn More